29.05.2017 • NewsBiopharmaElaine BurridgeJSR

JSR Life Sciences Expands US Biopharma Plants

(c) Steve Debenport/Getty Images
(c) Steve Debenport/Getty Images

JSR Life Sciences (JLS), a division of Japan’s JSR Corp., is expanding its biopharmaceutical manufacturing capacity in the US. JLS subsidiary, KBI Biopharma (KBI), is spending about $30 million to extend its capabilities at its plants in Durham, North Carolina and Boulder, Colorado. Both projects are scheduled for completion later this year.

KBI is building commercial mammalian cell culture facilities at the Durham site, which also houses cGMP cell culture manufacturing lines for clinical production. The investment will see two 2,000 liter single-use bioreactors installed as well as a full range of recovery and downstream purification suites that will enhance the plant’s existing process development, analytical and formulation development services.

At the Boulder plant, which currently offers commercial manufacturing capacity for microbial processes at 1,500 liter scale, KBI is building a second train with 300 liter scale fermentation capability to leverage single-use technologies. KBI said the additional smaller-scale capacity will ensure that it can continue to meet the process development and clinical manufacturing needs of its customers.

In addition, JSR subsidiary, JSR Micro, also plans to open an analytical services laboratory in Leuven, Belgium, in the first quarter of 2018, allowing it to offer analytical characterization and cGMP testing services to the European market.

The Belgian laboratory will also facilitate the continued collaboration between KBI and JLS to expand and enhance JLS’ Amsphere A3 product line. JLS said Amsphere A3, a next-generation protein A chromatography resin used for advanced antibody purification, has been rapidly adopted since its launch in January 2016. As a result, production in Leuven is being expanded by six times its current level, although the company did not give any actual figures.

The first phase of the expansion started earlier this year with plans to be fully operational in 2018. JLS said the multi-phased project will keep pace with growing demand for Amsphere A3 with the total additional capacity due for completion by the end of its fiscal year 2019.

JLS was formed in April 2016 as its Tokyo parent wanted to leverage its material and polymer expertise to expand into bioprocessing and diagnostic and research products. In bioprocessing, JLS focuses on large-scale purification and chromatography products including Amsphere A3. JSR acquired a majority stake in contract development and manufacturing organization KBI Biopharma in 2015.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.